研究者業績

西山 悠也

ニシヤマ ユウヤ  (nishiyama yuya)

基本情報

所属
藤田医科大学 医学部 脳神経外科 講師
学位
医学博士(藤田保健衛生大学)

J-GLOBAL ID
201601014567541368
researchmap会員ID
7000015628

専門分野
脳腫瘍(良性、悪性)手術
神経内視鏡手術
片側顔面けいれん、三叉神経痛
眼窩内腫瘍


委員歴

 2

論文

 34
  • 大場 茂生, 須藤 保, 杉原 英志, 山田 勢至, 西山 悠也, 安達 一英, 河田 健司, 安部 雅人, 佐谷 秀行, 廣瀬 雄一
    Brain Tumor Pathology 41(Suppl.) 100-100 2024年5月  
  • Yuya Nishiyama, Mitsuhiro Hasegawa, Kazuhide Adachi, Yuichi Hirose
    World neurosurgery 2024年1月6日  
    BACKGROUND: In >70% of patients with hemifacial spasm (HFS), the offending artery is either the anterior inferior cerebellar artery (AICA) or posterior inferior cerebellar artery (PICA), without a tortuous vertebrobasilar artery (VBA). We hypothesized that anchoring perforators around the root exit zone (REZ) of the AICA or PICA might induce vascular deviation and compression. We investigated the occurrence of these perforators from the AICA or PICA and the extent of VBA tortuosity to reveal the pathology of vascular compression. METHODS: This retrospective review included 110 patients after excluding those with vertebral artery (VA) compression alone. The occurrence of perforators was determined according to operative findings within 5 mm of the REZ, and VBA tortuosity was evaluated using MATLAB. We analyzed the association between perforators, VBA tortuosity, and the surgical implications. RESULTS: The occurrence of perforators from the offending AICA or PICA around the REZ was significantly higher in the group without VA compression (Group A) than in the group with VA compression (Group B). VBA tortuosity was significantly lower in Group A. VBA tortuosity was inversely correlated with the presence of AICA or PICA perforators in all 110 patients. Operative results were similar between the groups, although patients with low VBA tortuosity tended to require interposition in decompression procedures. CONCLUSIONS: Anchoring perforators around the REZ play a crucial role in vascular compression for patients with less tortuous VBAs. Moreover, surgeons should be prepared to deal with multiple perforators in a more complicated surgery in cases of less tortuous VBA.
  • 淳 武藤, 裕 峯, 悠也 西山, 基治 早川, 和宏 村山, 雄一 廣瀬
    Folia Endocrinologica Japonica 99(S.HPT) 46-47 2023年8月31日  
  • 大場 茂生, 杉原 英志, 山田 勢至, 中江 俊介, 西山 悠也, 武藤 淳, 安達 一英, 安部 雅人, 佐谷 秀行, 廣瀬 雄一
    Brain Tumor Pathology 40(Suppl.) 061-061 2023年5月  
  • 小嶋 大二朗, 桑原 聖典, 川副 雄史, 西山 悠也, 森谷 茂太, 廣瀬 雄一
    日本メディカルイラストレーション学会学術集会・総会 7回 E-2 2023年3月  
  • Jun Muto, Yutaka Mine, Yuya Nishiyama, Kazuhiro Murayama, Motoharu Hayakawa, Mitsuhiro Hasegawa, John K.Y. Lee, Yuichi Hirose
    World Neurosurgery 2023年3月  
  • Hikaru Sasaki, Tokunori Kanazawa, Yohei Kitamura, Masato Nakaya, Hirokazu Fujiwara, Tokuhiro Kimura, Shunsuke Nakae, Shigeo Ohba, Yuya Nishiyama, Masahiro Toda, Kazunari Yoshida, Yuichi Hirose
    Neuro-Oncology Advances 4(Supplement_3) iii27-iii27 2022年12月3日  
    Abstract Background In glioma surgery, both of functional preservation and maximal safe resection are critical, however, neoadjuvant strategy has never been used because of difficulty of tissue sampling without craniotomy. Method In Keio University Hospital, oligodendrogliomas, i.e., diffuse gliomas with IDH mutation and 1p/19q codeletion, with incomplete initial resection have been treated by upfront chemotherapy and subsequent resection after tumor volume decrease (second look resection, SLR) since 2006 (J Neurooncol 124:127-35, 2015). At first, initial radiotherapy was prescribed immediately after chemotherapy or SLR only for the cases with aggressive clinical course or subarachnoid infiltration, however, cases with residual FLAIR abnormality after upfront chemotherapy or SLR were also subjected to initial radiotherapy since 2018. Cases 1) with IDH mutation and 1p/19q codeletion, and 2) without history of either chemotherapy or radiotherapy, and 3) treated with upfront chemotherapy and subsequent resection strategy, were included. Results Thirty nine cases of oligodendroglioma have been treated with the above strategy since 2006. Tumor volume decrease following upfront chemotherapy was 30-35% (median), and 19 tumors underwent SLR. Among the total 39 cases, PFS and OS after initiation of upfront chemotherapy were 81 months and not reached, respectively, and were 64 months and not reached, respectively, among the 32 cases with deferred radiotherapy. Importantly, the majority of tumor recurrence occurred at the residual FLAIR abnormality following upfront chemotherapy. Conclusions Treatment of oligodendrogliomas utilizing neoadjuvant strategy enables 1) decrease of resection volume as compared with initial maximal safe resection, 2) more precise resection, 3) confirmation of the necessity of initial radiotherapy based on the observed efficacy of chemotherapy. Moreover, the study also suggested that 4) invasion front of oligodendroglioma likely withdraw by alkylating agents, and 5) cases with residual FLAIR abnormality following chemotherapy may be appropriate subjects for initial radiotherapy.
  • Jun Muto, Yutaka Mine, Yuya Nishiyama, Kazuhiro Murayama, Seiji Yamada, Daijiro Kojima, Motoharu Hayakawa, Kazuhide Adachi, Mitsuhiro Hasegawa, John Y. K. Lee, Yuichi Hirose
    Frontiers in Neuroscience 16 837349-837349 2022年5月4日  
    Meningiomas are a common pathology in the central nervous system requiring complete surgical resection. However, in cases of recurrence and post-irradiation, accurate identification of tumor remnants and a dural tail under bright light remains challenging. We aimed to perform real-time intraoperative visualization of the meningioma and dural tail using a delayed-window indocyanine green (ICG) technique with microscopy. Fifteen patients with intracranial meningioma received 0.5 mg/kg ICG a few hours before observation during the surgery. We used near-infrared (NIR) fluorescence to identify the tumor location. NIR fluorescence could visualize meningiomas in 12 out of 15 cases. Near-infrared visualization during the surgery ranged from 1 to 4 h after the administration of ICG. The mean signal-to-background ratio (SBR) of the intracranial meningioma in delayed-window ICG (DWIG) was 3.3 ± 2.6. The ratio of gadolinium-enhanced T1 tumor signal to the brain (T1BR) (2.5 ± 0.9) was significantly correlated with the tumor SBR (p = 0.016). Ktrans, indicating blood–brain barrier permeability, was significantly correlated with tumor SBR (p < 0.0001) and T1BR (p = 0.013) on dynamic contrast-enhanced magnetic resonance imaging (MRI). DWIG demonstrated a sensitivity of 94%, specificity of 38%, positive predictive value (PPV) of 76%, and negative predictive value (NPV) of 75% for meningiomas. This is the first pilot study in which DWIG fluorescence-guided surgery was used to visualize meningioma and dural tail intraoperatively with microscopy. DWIG is comparable with second-window ICG in terms of mean SBR. Gadolinium-enhanced T1 tumor signal may predict NIR fluorescence of the intracranial meningioma. Blood–brain barrier permeability as shown by Ktrans on dynamic contrast-enhanced MRI can contribute to gadolinium enhancement on MRI and to ICG retention and tumor fluorescence by NIR.
  • 武藤 淳, 谷川 篤宏, 藤沢 治樹, 西山 悠也, 伊藤 逸毅, 鈴木 敦詞, 長谷川 光広, 廣瀬 雄一
    日本内分泌学会雑誌 98(1) 279-279 2022年4月  
  • 松本 沙弓, 吉野 寧維, 轟木 秀親, 岡本 慧子, 西山 悠也, 清野 祐介, 廣瀬 雄一, 鈴木 敦詞
    日本内分泌学会雑誌 98(1) 333-333 2022年4月  
  • Kiyonori Kuwahara, Shigeta Moriya, Ichiro Nakahara, Tadashi Kumai, Shingo Maeda, Yuya Nishiyama, Midoriko Watanabe, Yoshikazu Mizoguchi, Yuichi Hirose
    Surgical neurology international 13 268-268 2022年  
    Background: Cerebral amyloid angiopathy-related inflammation (CAA-I) presents with slowly progressive nonspecific neurological symptoms, such as headache, cognitive function disorder, and seizures. Pathologically, the deposition of amyloid-β proteins at the cortical vascular wall is a characteristic and definitive finding. Differential diagnoses include infectious encephalitis, neurosarcoidosis, primary central nervous system lymphoma, and glioma. Here, we report a case of CAA-I showing acute progression, suggesting a glioma without enhancement, in which a radiological diagnosis was difficult using standard magnetic resonance imaging. Case Description: An 80-year-old woman was admitted due to transient abnormal behavior. Her initial imaging findings were similar to those of a glioma. She presented with rapid progression of the left hemiplegia and disturbance of consciousness for 6 days after admission and underwent emergent biopsy with a targeted small craniotomy under general anesthesia despite her old age. Intraoperative macroscopic findings followed by a pathological study revealed CAA-I as the definitive diagnosis. Steroid pulse therapy with methylprednisolone followed by oral prednisolone markedly improved both the clinical symptoms and imaging findings. Conclusion: Differential diagnosis between CAA-I and nonenhancing gliomas may be difficult using standard imaging studies in cases presenting with acute progression. A pathological diagnosis under minimally invasive small craniotomy may be an option, even for elderly patients.
  • Yushi Kawazoe, Shigeo Ohba, Kazuhiro Murayama, Shunsuke Nakae, Yuya Nishiyama, Masato Abe, Mitsuhiro Hasegawa, Yuichi Hirose
    World neurosurgery 158 e820-e828 2021年11月20日  
    BACKGROUND: We investigated the ability of magnetic resonance imaging (MRI) to distinguish primary central nervous system vasculitis (PCNSV) from glioblastoma to facilitate the development of an appropriate treatment for PCNSV. METHODS: We enrolled patients who were treated for PCNSV or glioblastoma at our center between January 2007 and August 2018. We compared the diagnoses of the 2 conditions by retrospectively reviewing patients' data for contrast-enhanced MRI, perfusion MRI, flow-sensitive black-blood (FSBB) imaging, and 1H-magnetic resonance spectroscopy (MRS). RESULTS: We evaluated 108 patients (6 PCNSV; 102 glioblastoma). We found a statistically significant correlation between diagnosis and the contrast pattern on MRI. Perivascular enhancement was observed in all cases of PCNSV as follows: ring-like, homogeneous, and irregular patterns were observed in 53 (60%), 18 (20%), and 17 (19%) cases of glioblastoma, respectively. We identified a statistically significant correlation between diagnosis and cerebral blood volume (CBV) in 3 patients with PCNSV who underwent perfusion MRI; and all had low CBVs. Among the 55 patients with glioblastoma who underwent perfusion MRI, low and high CBVs were detected in 3 and 52 patients, respectively. There was no significant correlation between diagnosis and FSBB findings. Evaluation of 1H-MRS data showed statistically significant differences between PCNSV and glioblastoma as functions of neuronal amino acid levels on long echo time MRS, with a slightly different amino acid profile, including glutamine + glutamate on short echo time MRS. CONCLUSIONS: Contrast-enhanced MRI, perfusion MRI, and quantitative analysis of 1H-MRS are valuable techniques for distinguishing PCNSV from glioblastoma before surgery.
  • Kazuhide Adachi, Kazuhiro Murayama, Motoharu Hayakawa, Mitsuhiro Hasegawa, Jun Muto, Yuya Nishiyama, Shigeo Ohba, Yuichi Hirose
    Neurosurgical review 44(5) 2629-2638 2021年10月  
    Digital subtraction angiography (DSA) assesses the necessity of preoperative embolization in meningioma cases but entails complication risks. Previous studies evaluating meningiomas' angiographic vascularity using perfusion-weighted imaging (PWI) have performed subjective visual assessments, not managing to assess the need for preoperative embolization. We objectively assessed the angiographic stain of meningiomas and examined the usefulness of two parameters of dynamic susceptibility contrast (DSC)-PWI, normalized cerebral blood volume (nCBV) and cerebral blood flow (nCBF), in predicting vascularity and the necessity of preoperative embolization. We retrospectively examined 52 patients who underwent surgery for primary meningioma and preoperative DSA and DSC-PWI. We calculated the normalized luminance (nLum) of the tumor stain in DSA. In 29 meningioma cases with a single feeding artery, we determined the DSC-PWI parameter that correlated with meningioma angiographic vascularity and predicted the necessity of preoperative embolization. We also compared vascularity between meningiomas with single and multiple feeding arteries and between convexity and skull-base meningiomas. nCBF (cut off: 3.66, P = 0.03, area under the curve [AUC] = 0.80) alone could predict the necessity of preoperative embolization and was more significantly correlated with the nLum than nCBV (P = 0.08, AUC = 0.73). Vascularity did not differ between meningiomas with single and multiple feeding arteries; skull-base meningiomas were more vascularized than convexity meningiomas (P = 0.0027). Our objective, quantitative assessments revealed nCBF as the most suitable parameter for evaluating meningioma vascularity. Tumor vascularity assessment using nCBF values and CBF images may aid predicting the necessity of preoperative DSA.
  • Kiyonori Kuwahara, Shigeo Ohba, Kazuyasu Matsumura, Saeko Higashiguchi, Daijiro Kojima, Jun Muto, Shunsuke Nakae, Yuya Nishiyama, Seiji Yamada, Kazuhide Adachi, Masato Abe, Mitsuhiro Hasegawa, Yuichi Hirose
    Neuro-Oncology Advances 2(Supplement_3) ii18-ii18 2020年11月1日  
    Abstract Background: Although high dose-methotrexate therapy has been performed for primary central nervous system malignant lymphoma (PCNSL), R-MPV (rituximab, methotrexate (MTX), procarbazine and vincristine) therapy is currently the first line therapy for (PCNSL) in our hospital. This study examines the results of R-MPV therapy comparing with past treatment. Method/Subjects: Thirty-seven patients treated at our hospital from 2009 to 2020 were included. Overall survival time, progression free survival time, and toxicities were evaluated. Results: The average age of patients was 65.7 years. Patients included 21 males and 16 females. Thirty-six patients were diagnosed DLBCL by resected brain tumor tissues, and one was diagnosed DLBCL by vitreous biopsy. As initial treatment, rituximab±HD-MTX therapy (R±MTX group) was performed in 20 cases, HD-MTX therapy plus radiation (R±MTX+RT group) was performed in 12 cases, and RMPV therapy was performed in 5 cases (R-MPV group). Median OS of all cases was 69 months and median PFS was 38 months. Median OS was 69 months in R±MTX group and could not be calculated in R±MTX+RT, and R-MPV groups. Median PFS was 16 months and 56 months in R±MTX group and R±MTX+RT, respectively, and could not be calculated in the R-MPV group. Although the R-MPV group had a short follow-up period, the results were considered to be comparable to those of the R±MTX+RT group. On the other hand, grade 3/4 adverse events occurred in 50%, 25%, and 100%, respectively. Conclusion: R-MPV therapy may delay the timing of radiation and reduce the amount of radiation. On the other hand, the frequency of adverse events is high, and more strict management of treatment is required.
  • Shigeo Ohba, Kazuhiro Murayama, Kiyonori Kuwahara, Eriel Sandika Pareira, Shunsuke Nakae, Yuya Nishiyama, Kazuhide Adachi, Seiji Yamada, Hikaru Sasaki, Naoki Yamamoto, Masato Abe, Joydeep Mukherjee, Mitsuhiro Hasegawa, Russell O Pieper, Yuichi Hirose
    Neurosurgery 87(2) 408-417 2020年8月1日  
    BACKGROUND: The extent of resection has been reported to be associated with overall survival in gliomas. The use of 5-aminolevulinic acid (5-ALA) has been recognized to increase the extent of tumor resection. OBJECTIVE: To evaluate what factors affect the intraoperative fluorescence after administration of 5-ALA in gliomas. METHODS: Correlation of intraoperative fluorescence and several clinical, radiographic, molecular biologic, and histopathologic characters was retrospectively evaluated in 104 patients (53 males and 51 females; mean age 54.2 yr) with gliomas at our institution. To clarify the mechanisms that mutant isocitrate dehydrogenase (IDH) affect the intraoperative fluorescence, in Vitro experiments using genetically engineered glioma cells harboring mutant IDH1 were performed. RESULTS: Intraoperative fluorescence was observed in 82 patients (78.8%). In addition to age, magnetic resonance imaging enhancement, World Health Organization grades, and MIB-1 index, the status of IDH was revealed to be correlated with intraoperative fluorescence. In Vitro assay revealed that mutant IDH indirectly reduced the amount of exogenous 5-ALA-derived protoporphyrinogen IX in glioma cells by increasing activity of ferrochelatase and heme oxygenase 1. CONCLUSION: Mutant IDH1/2-induced metabolite changes of exogenous 5-ALA were suggested to contribute to the lesser intraoperative fluorescence in gliomas with mutant IDH1/2 than in those without.
  • Mitsuhiro Hasegawa, Toru Hatayama, Akinori Kondo, Shinji Nagahiro, Takamitsu Fujimaki, Kenichi Amagasaki, Kazunori Arita, Isao Date, Yukihiko Fujii, Takeo Goto, Ryosuke Hanaya, Yoshinori Higuchi, Kazuhiro Hongo, Toru Inoue, Hidetoshi Kasuya, Takamasa Kayama, Masatou Kawashima, Eiji Kohmura, Taketoshi Maehara, Toshio Matsushima, Yoshihumi Mizobuchi, Akio Morita, Shigeru Nishizawa, Shusaku Noro, Shinjiro Saito, Hirofumi Shimano, Reizo Shirane, Hideo Takeshima, Yuichiro Tanaka, Hidenori Tanabe, Hiroki Toda, Iwao Yamakami, Yuya Nishiyama, Shigeo Ohba, Yuichi Hirose, Takeya Suzuki
    World neurosurgery 134 685-685 2020年2月  
  • 花松 智武, 村山 和宏, 西山 悠也, 小濱 佑樹, 植田 高弘, 池田 裕隆, 山田 勢至, 安倍 雅人, 大野 良治, 外山 宏
    映像情報Medical 52(1) 84-85 2020年1月  査読有り
  • Hasegawa M, Hatayama T, Kondo A, Nagahiro S, Fujimaki T, Amagasaki K, Arita K, Date I, Fujii Y, Goto T, Hanaya R, Higuchi Y, Hongo K, Inoue T, Kasuya H, Kayama T, Kawashima M, Kohmura E, Maehara T, Matsushima T, Mizobuchi Y, Morita A, Nishizawa S, Noro S, Saito S, Shimano H, Shirane R, Takeshima H, Tanaka Y, Tanabe H, Toda H, Yamakami I, Nishiyama Y, Ohba S, Hirose Y, Suzuki T
    World neurosurgery 130 e251-e258 2019年6月  査読有り
  • Ohba S, Murayama K, Nishiyama Y, Adachi K, Yamada S, Abe M, Hasegawa M, Hirose Y
    World neurosurgery 130 e383-e392 2019年6月  査読有り
  • 大場 茂生, 村山 和宏, 中江 俊介, 安達 一英, 西山 悠也, 佐々木 光, 山田 勢至, 安倍 雅人, 長谷川 光広, 廣瀬 雄一
    Brain Tumor Pathology 36(Suppl.) 084-084 2019年5月  
  • Tokunori Kanazawa, Hirokazu Fujiwara, Hidenori Takahashi, Yuya Nishiyama, Yuichi Hirose, Saeko Tanaka, Kazunari Yoshida, Hikaru Sasaki
    Neurosurgical Review 42(2) 1-9 2018年4月26日  査読有り
  • Kazuhiro Murayama, Yuya Nishiyama, Yuichi Hirose, Masato Abe, Shigeharu Ohyu, Ayako Ninomiya, Takashi Fukuba, Kazuhiro Katada, Hiroshi Toyama
    Magnetic Resonance in Medical Sciences 17(1) 42-49 2018年  査読有り
  • Shigeta Moriya, Shigeo Ohba, Kazuhide Adachi, Yuya Nishiyama, Takuro Hayashi, Shinya Nagahisa, Takafumi Kaito, Shunsuke Nakae, Yuichi Hirose
    Journal of Clinical Neuroscience 47 228-233 2018年1月1日  査読有り
  • Shunsuke Nakae, Kazuhiro Murayama, Hikaru Sasaki, Masanobu Kumon, Yuya Nishiyama, Shigeo Ohba, Kazuhide Adachi, Shinya Nagahisa, Takuro Hayashi, Joji Inamasu, Masato Abe, Mitsuhiro Hasegawa, Yuichi Hirose
    JOURNAL OF NEURO-ONCOLOGY 131(2) 403-412 2017年1月  査読有り
  • Natsuki Hattori, Yuichi Hirose, Hikaru Sasaki, Shunsuke Nakae, Saeko Hayashi, Shigeo Ohba, Kazuhide Adachi, Takuro Hayashi, Yuya Nishiyama, Mitsuhiro Hasegawa, Masato Abe
    CANCER SCIENCE 107(8) 1159-1164 2016年8月  査読有り
  • Shunsuke Nakae, Hikaru Sasaki, Saeko Hayashi, Natsuki Hattori, Masanobu Kumon, Yuya Nishiyama, Kazuhide Adachi, Shinya Nagahisa, Takuro Hayashi, Joji Inamasu, Masato Abe, Mitsuhiro Hasegawa, Yuichi Hirose
    PLOS ONE 10(11) e0142750 2015年11月  査読有り
  • Roberto Gazzeri, Yuya Nishiyama, Charles Teo
    NEUROSURGICAL FOCUS 37(4) E20 2014年10月  査読有り
  • Yuya Nishiyama, Hikaru Sasaki, Shinya Nagahisa, Kazihide Adachi, Takuro Hayashi, Koichiro Yoshida, Tsukasa Kawase, Natsuki Hattori, Kazuhiro Murayama, Masato Abe, Mitsuhiro Hasegawa, Yuichi Hirose
    NEUROSURGICAL REVIEW 37(2) 291-299 2014年4月  査読有り
  • Hikaru Sasaki, Yuya Nishiyama, Kazunari Yoshida
    Japanese Journal of Cancer and Chemotherapy 41(6) 709-712 2014年  査読有り
  • Shinya Nagahisa, Takeya Watabe, Hikaru Sasaki, Yuya Nishiyama, Takuro Hayashi, Mitsuhiro Hasegawa, Yuichi Hirose
    NEUROSURGICAL REVIEW 36(4) 595-600 2013年10月  査読有り
  • Yuichi Hirose, Hikaru Sasaki, Masato Abe, Natsuki Hattori, Kazuhide Adachi, Yuya Nishiyama, Shinya Nagahisa, Takuro Hayashi, Mitsuhiro Hasegawa, Kazunari Yoshida
    BRAIN TUMOR PATHOLOGY 30(4) 203-208 2013年10月  査読有り
  • Joji Inamasu, Takeya Watabe, Tsukasa Ganaha, Yasuhiro Yamada, Shunsuke Nakae, Tatsuo Ohmi, Shuei Imizu, Takafumi Kaito, Keisuke Ito, Yuya Nishiyama, Takuro Hayashi, Hirotoshi Sano, Yoko Kato, Yuichi Hirose
    JOURNAL OF CLINICAL NEUROSCIENCE 20(8) 1095-1098 2013年8月  査読有り
  • Joji Inamasu, Shunsuke Tanoue, Takeya Watabe, Shuei Imizu, Takafumi Kaito, Keisuke Ito, Natsuki Hattori, Yuya Nishiyama, Takuro Hayashi, Yoko Kato, Yuichi Hirose
    Neurosurgical review 36(3) 447-54 2013年7月  
    Seizures occurring after clipping of unruptured cerebral aneurysms have rarely been documented in the literature. The objective of this retrospective study is to clarify whether the frequency of early seizures, i.e., seizures occurring within 14 days of surgery, is influenced by patient- or aneurysm-specific characteristics. Data on 1,000 consecutive patients who underwent clipping of unruptured anterior circulation aneurysms were reviewed. They consisted of 387 men and 613 women with mean age of 59.8 ± 9.7 years. Fifty-one patients (5.1 %) developed early seizures. Interestingly, the frequency was similar to that occurring after clipping of unruptured posterior circulation aneurysms (n = 20, 5.0 %). Multivariate regression analysis revealed that younger age was correlated with early seizures (odds ratio (OR) 0.902; 95 % confidence interval (CI) 0.891-0.989). However, other variables, including aneurysm size and operation length, were not correlated. Although patients with history of epilepsy exhibited relatively high frequency of early seizures, the difference was not statistically significant. The frequency was unaffected by location or multiplicity of aneurysms. Thirty-one patients (61 %) developed seizures within 24 h of clipping. Regarding seizure types, 34 (67 %) developed generalized seizures and the other 17 (33 %) experienced partial seizures. Patients with generalized seizures were significantly more likely to harbor an iatrogenic brain lesion than those with partial seizures (47 vs. 18 %; OR 4.148; 95 % CI 1.005-17.113). Among 40 patients with follow-up period >12 months, seizures were temporary without recurrence in 38 (95 %). Although early seizures are mostly benign, a small possibility of them becoming a permanent morbidity needs to be explained to patients undergoing elective clipping.
  • Nikolay A. Peev, Yuichi Hirose, Tatsuo Hirai, Yuya Nishiyama, Shinya Nagahisa, Testuo Kanno, Hirotoshi Sano
    NEUROSURGICAL REVIEW 33(3) 349-357 2010年7月  査読有り

MISC

 111

講演・口頭発表等

 43